Issues related to prior authorization.
2025 · 3rd Quarter (July 1 - Sep 30)
THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Filed by THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES).
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- Not reported
- Expenses
- $1,370,000.00
- Filing UUID
- 133c499a-e4b1-438d-b78c-7d14ed245594
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation, inclusion of PBM reform and other health policies; Issues relating to implementation of the No Surprises Act.
H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.
S. 1542/H.R. 2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market; Issues related to transparency.
Literal federal measure citations: S. 1542, H.R. 2214, H.R. 5378, S. 1339, S.526, S. 1040, S. 1041
Issues related to competition in the health care marketplace.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.